DENTAL-MONITORING
16.3.2020 19:13:09 CET | Business Wire | Press release
Dental Monitoring tele dentistry solutions allow dental professionals to connect with their patients remotely and in a HIPAA compliant manner. Our unique technology enables dentists and orthodontists to assess, monitor treatment, and communicate with their patients as much as needed, even when they are at home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005750/en/
Given the unprecedented situation we are facing worldwide, and with patient access to practices becoming more difficult, Dental Monitoring’s priorities have shifted to supporting all dental professionals whoever and wherever they are, to continue the care of their patients, as well as ensuring the continuity of their practices. Our current solutions use the full extent of our AI engine, and complete onboarding for practices can often take a few weeks to integrate fully. Therefore we have decided to refocus our company priorities to launch immediately two new “Light ” versions of our existing solutions. These new versions will be simpler and more immediate to implement for these times - rapid on-boarding and roll-out to all patients:
Photo Monitoring Light :
Simplified at-home monitoring platform with instant two-way communication with patients.
Capturing pictures of the mouth through the DM App allowing doctors to :
- Evaluate remotely their patients' current oral situation or treatment progress as if they were in the practice
- Have two way communication and guidance between doctor and patient
- Send annotated pictures directly via the patient App so patients can better understand their doctor’s guidance.
Photo Monitoring Light will also enable the clinical team to request an immediate DM scan when a patient requests immediate feedback, so that the doctor can better evaluate the patient’s situation and advise accordingly.
To implement Photo Monitoring Light: please visit https://dental-monitoring.com/maintain-patient-care/
SmileMate Virtual Consultation:
Remote assessment of new and existing patients.
All patient calls can be pre-qualified remotely using the SmileMate assessment tool directly through doctors practice websites.
The process is simple:
Step 1- The patient clicks on the widget on the doctor’s website, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an app or use cheek retractors)
Step 2- A comprehensive customized report and treatment option is automatically generated by our AI engine and sent to the doctor
Step 3- Doctors qualify the patient’s needs on their SmileMate portal
Step 4- Doctors customize and share the report with the patient with advice or a booking link.
To implement SmileMate Virtual Consultation please visit: https://dental-monitoring.com/maintain-patient-care/
Fast-Track Accelerated On-Boarding.
Photo Monitoring Light and SmileMate Virtual Consultation are ready for use in minutes after doctors and their teams have performed our free fast-track accelerated training. Implementing fast-track onboarding into dental practices is simplified through our new streamlined process, which is done 100% remotely through webinars by our customer support team.
Call us or visit: https://dental-monitoring.com/maintain-patient-care/
to book a time slot for our next training session.
Opening up a dedicated 24/7 hotline to answer any questions or needs during the pandemic.
Our priority has always been our customers and their patients. Over the next few months, we will be solely focused on delivering solutions that can help doctors maintain the expert care they provide to their patients. To that extent, and during the pandemic, we will maximize accessibility to our solutions by reducing our price on these new solutions by 50% :
- Photo Monitoring Light will be accessible for US$3 per month/patient monitored
- For SmileMate Virtual Consultation will be at US$150/month for 50 unique patient scans
We have also directed our worldwide sales force to focus 100% on Customer Service - working side by side with doctors to help treat their patients remotely.
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States, and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom